Please note that following on from information received from the company, NICE has decided to suspend this appraisal from its current work programme. The timelines for this appraisal are to be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this appraisal will be available in due course.
NICE will continue to monitor any development and will update interested parties as and when the situation changes.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Process | STA Standard |
| ID number | 3844 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 12 January 2024 | Suspended. Please note that following on from information received from the company, NICE has decided to suspend this appraisal from its current work programme. The timelines for this appraisal are to be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this appraisal will be available in due course. NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 27 April 2023 | Please note that following an update received from the company this appraisal is still to be rescheduled to align with latest regulatory expectations. Further information regarding the timelines for this appraisal will be available during second half 2023. |
For further information on our processes and methods, please see our CHTE processes and methods manual